The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
Open accessAbstract
Traditional treatments for type 1 and type 2 diabetes are often associated with side effects, including weight gain and hypoglycaemia that may offset the benefits of blood glucose lowering. The kidneys filter and reabsorb large amounts of glucose, and urine is almost free of glucose in normoglycaemia. The sodium-dependent glucose transporter (SGLT)-2 in the early proximal tubule reabsorbs the majority of filtered glucose. Remaining glucose is reabsorbed by SGLT1 in the late proximal tubule. Diabetes enhances renal glucose reabsorption by increasing the tubular glucose load and the expression of SGLT2 (as shown in mice), which maintains hyperglycaemia. Inhibitors of SGLT2 enhance urinary glucose excretion and thereby lower blood glucose levels in type 1 and type 2 diabetes. The load-dependent increase in SGLT1-mediated glucose reabsorption explains why SGLT2 inhibitors in normoglycaemic conditions enhance urinary glucose excretion to only ~50% of the filtered glucose. The role of SGLT1 in both renal and intestinal glucose reabsorption provides a rationale for the development of dual SGLT1/2 inhibitors. SGLT2 inhibitors lower blood glucose levels independent of insulin and induce pleiotropic actions that may be relevant in the context of lowering cardiovascular risk. Ongoing long-term clinical studies will determine whether SGLT2 inhibitors have a safety profile and exert cardiovascular benefits that are superior to traditional agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inhibitors of sodium-glucose cotransporter 2 reduce rates of hyperglycemia in patients with type 2 diabetes by decreasing renal glucose reabsorption, thereby increasing urinary glucose excretion. 10”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [10]
In the citing paper
“Sodium/glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels by preventing glucose and sodium reabsorption in the proximal tubule (8–10).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. V. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,676
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Research works printed but not linked: 6
- International Diabetes Federation, 2013, IDF diabetes Atlas
- Barfuss DW, 1981, Am J Physiol, 241, F322
- Turner RJ, 1982, Am J Physiol, 242, F406
- Wells RG, 1992, Am J Physiol, 263, F459
- Petersen C., 1835, Annales Académie Science Française, 15, 178
- von Mering J., 1886, Centralbl Med Wiss, 531
Cited by
Sorted by citations
Items 101–200 of 395
QSAR studies in the discovery of novel type-II diabetic therapies
Abuhammad, A., & Taha, M. O. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1118046 · Cited by 38
Positron emission tomography of sodium glucose cotransport activity in high grade astrocytomas
Kepe, V., Scafoglio, C., Liu, J., Yong, W. H., Bergsneider, M., Huang, S., Barrio, J. R., & Wright, E. M. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2823-7 · Cited by 38
Self-citationSodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects
Satirapoj, B. (2017) · Kidney Diseases · doi:10.1159/000471765 · Cited by 37
Intestinal absorption of glucose in mice as determined by positron emission tomography
Sala‐Rabanal, M., Ghezzi, C., Hirayama, B. A., Kepe, V., Liu, J., Barrio, J. R., & Wright, E. M. (2018) · The Journal of Physiology · doi:10.1113/jp275934 · Cited by 37
Self-citationHeo, C. U., & Choi, C. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030393 · Cited by 40
Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus
Feng, M., Lv, H., Xu, X., Wang, J., Lyu, W., & Fu, S. (2019) · Medicine · doi:10.1097/md.0000000000016575 · Cited by 40
Trnovská, J., Svoboda, P., Pelantová, H., Kuzma, M., Kratochvílová, H., Kasperová, B. J., Pleyerová, I., ROSOLOVÁ, K., Malínská, H., Hüttl, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910606 · Cited by 38
Huang, S., Wu, B., He, Y., Qiu, R., Yang, T., Wang, S., Lei, Y., Li, H., & Zheng, F. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000045 · Cited by 37
SGLT inhibitors as antidiabetic agents: a comprehensive review
Kshirsagar, R. P., Kulkarni, A. A., Chouthe, R. S., Pathan, S. K., Une, H. D., Reddy, G. B., Diwan, P. V., Ansari, S. A., & Sangshetti, J. N. (2020) · RSC Advances · doi:10.1039/c9ra08706k · Cited by 40
Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review
Mollace, V., Rosano, G. M. C., Anker, S. D., Coats, A. J. S., Seferovic, P. M., Mollace, R., Tavernese, A., Gliozzi, M., Musolino, V., Carresi, C., et al. (2021) · Nutrients · doi:10.3390/nu13010257 · Cited by 35
McPherson, K. C., Shields, C. A., Poudel, B., Fizer, B., Pennington, A., Szabo-Johnson, A., Thompson, W. L., Cornelius, D. C., & Williams, J. M. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00162.2018 · Cited by 34
Advances in the Treatment Strategies in Hypertension: Present and Future
Verdecchia, P., Cavallini, C., & Angeli, F. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9030072 · Cited by 43
Eldesoqui, M. B., Eldken, Z. H., Mostafa, S. A., Al‐Serwi, R. H., El‐Sherbiny, M., Elsherbiny, N. M., Mohammedsaleh, Z. M., & Sakr, N. H. (2022) · Metabolites · doi:10.3390/metabo12070635 · Cited by 34
Jiang, Y., Yang, P., Fu, L., Sun, L., Shen, W., & Wu, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.802992 · Cited by 34
Scholtes, R. A., van Baar, M. J. B., Lytvyn, Y., Bjornstad, P., Nieuwdorp, M., Cherney, D. Z. I., & van Raalte, D. H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13692 · Cited by 34
Shah, N. Z., Abdalla, M. A., Deshmukh, H., & Sathyapalan, T. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211042145 · Cited by 39
Naeimzadeh, Y., Tajbakhsh, A., Nemati, M., & Fallahi, J. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176803 · Cited by 32
Kashiwagi, A., Araki, S., & Maegawa, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13329 · Cited by 32
Molecular signaling mechanisms of renal gluconeogenesis in nondiabetic and diabetic conditions
Swe, M. T., Pongchaidecha, A., Chatsudthipong, V., Chattipakorn, N., & Lungkaphin, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27598 · Cited by 31
New strategies and therapies for the prevention of heart failure in high‐risk patients
Hammond, M. M., Everitt, I., & Khan, S. S. (2022) · Clinical Cardiology · doi:10.1002/clc.23839 · Cited by 38
Khalaf, E. M., Hassan, H. M., El-Baz, A. M., Shata, A., Khodir, A. E., Yousef, M. E., Elgharabawy, R. M., Nouh, N. A. T., Saleh, S., Bin-Meferij, M. M., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175172 · Cited by 30
MicroRNA‐296‐5p promotes healing of diabetic wound by targeting sodium‐glucose transporter 2 (SGLT2)
Liu, X., Wang, Y., Zhang, X., Zhang, X., Guo, J., Zhou, J., Chai, Y., & Ma, Z. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3104 · Cited by 30
Ion channels and transporters in diabetic kidney disease
Spires, D. R., Manis, A. D., & Staruschenko, A. (2019) · Current topics in membranes · doi:10.1016/bs.ctm.2019.01.001 · Cited by 30
Yabe, D., Shiki, K., Suzaki, K., Meinicke, T. W., Kotobuki, Y., Nishida, K., Clark, D., Yasui, A., & Seino, Y. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045844 · Cited by 32
Rau, M., Thiele, K., Hartmann, N. K., Möllmann, J., Wied, S., Hohl, M., Marx, N., & Lehrke, M. (2022) · Bone Reports · doi:10.1016/j.bonr.2022.101175 · Cited by 33
SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells
Anastasio, C., Donisi, I., Vecchio, V. D., Colloca, A., Mele, L. L., Sardu, C., Marfella, R., Balestrieri, M. L., & D’Onofrio, N. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00599-1 · Cited by 29
Provenzano, M., Pelle, M. C., Zaffina, I., Tassone, B., Pujia, R., Ricchio, M., Serra, R., Sciacqua, A., Michael, A., Andreucci, M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.654557 · Cited by 30
Renal Tubular Handling of Glucose and Fructose in Health and Disease
Vallon, V., & Nakagawa, T. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210030 · Cited by 49
Self-citationIsmail‐Beigi, F., Moghissi, E. S., Kosiborod, M., & Inzucchi, S. E. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4061-7 · Cited by 28
Severino, P., D’Amato, A., Prosperi, S., Fanisio, F., Birtolo, L. I., Costi, B., Netti, L., Chimenti, C., Lavalle, C., Maestrini, V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147650 · Cited by 30
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 30
Saving the sweetness: renal glucose handling in health and disease
Shepard, B. D., & Pluznick, J. L. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00046.2017 · Cited by 28
Nakajima, H., Okada, S., Mohri, T., Kanda, E., Inaba, N., Hirasawa, Y., Seino, H., Kuroda, H., Hiyoshi, T., Niiya, T., et al. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0313-x · Cited by 28
“The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics”
Kaur, P., Behera, B. S., Singh, S., & Munshi, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174169 · Cited by 27
SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
Amin, N. U., Sabir, F., Amin, T., Sarfraz, Z., Sarfraz, A., Robles‐Velasco, K., & Chérrez-Ojeda, I. (2022) · Healthcare · doi:10.3390/healthcare10122356 · Cited by 27
Kumar, N., Kumar, B., Ashique, S., Yasmin, S., Venkatesan, K., Islam, A., Ghosh, S., Sahu, A., Bhui, U., & Ansari, M. Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112050 · Cited by 29
Cardio-sarcopenia: A syndrome of concern in aging
Loh, D. R., Tan, R., Lim, W. S., & Koh, A. S.-M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1027466 · Cited by 25
Shen, J., Yang, J., & Zhao, B. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0611-9 · Cited by 25
Eroglu, T. E., Coronel, R., Zuurbier, C. J., Blom, M. T., de Boer, A., & Souverein, P. C. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac043 · Cited by 25
Kessler, E. L., Oerlemans, M. I. F. J., van den Hoogen, P., Yap, C., Sluijter, J. P. G., & de Jager, S. C. A. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10026-3 · Cited by 27
SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
Kanduri, S. R., Kovvuru, K. R., Hansrivijit, P., Thongprayoon, C., Vallabhajosyula, S., Pivovarova, A. I., Chewcharat, A., Garla, V. V., Medaura, J. A., & Cheungpasitporn, W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092723 · Cited by 26
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease
Jiménez, D. L., Cherney, D. Z. I., Bjornstad, P., Castilla‐Guerra, L., & Miramontes‐González, J. P. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00384.2017 · Cited by 26
Patel, S. M., Hickman, A., Frederich, R. C., JOHNSON, S. L., Huyck, S. B., Mancuso, J. P., Gantz, I., & Terra, S. G. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00803-3 · Cited by 24
Pourfarjam, Y., Rezagholizadeh, L., Nowrouzi, A., Meysamie, A., Ghaseminejad, S., Ziamajidi, N., & Norouzi, D. (2016) · Renal Failure · doi:10.1080/0886022x.2016.1256317 · Cited by 24
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Brito, D. A., Bettencourt, P., Carvalho, D. M., Ferreira, J., Fontes‐Carvalho, R., Franco, F., Moura, B., Silva‐Cardoso, J., de Melo, R. T., & Fonseca, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06973-3 · Cited by 24
Is it time to think about the sodium glucose co‐transporter 2 sympathetically?
Elliott, R. H., Matthews, V. B., Rudnicka, C., & Schlaich, M. P. (2016) · Nephrology · doi:10.1111/nep.12620 · Cited by 23
Ito, D., Shimizu, S., Haisa, A., Yanagisawa, S., Inoue, K., Saito, D., Sumita, T., Yanagisawa, M., Uchida, Y., Inukai, K., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14246 · Cited by 24
New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
Hung, C., & Lu, L. (2024) · Neurology International · doi:10.3390/neurolint16060124 · Cited by 23
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 25
Rau, M., Thiele, K., Hartmann, N. K., Möllmann, J., Wied, S., Böhm, M., Scharnagl, H., März, W., Marx, N., & Lehrke, M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.915 · Cited by 23
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Kalra, S. (2016) · Cardiology and Therapy · doi:10.1007/s40119-016-0069-z · Cited by 23
MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer
Zhang, X., Zhang, X., Liu, X., Qi, P., Wang, H., Ma, Z., & Chai, Y. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4599 · Cited by 23
Shrestha, D. B., Budhathoki, P., Sedhai, Y. R., Karki, P., Gurung, S., Raut, S., Damonte, J. I., Buono, M. G. D., Mojadidi, M. K., Elgendy, I. Y., et al. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001099 · Cited by 23
Devineni, D., Akbarpour, M., Gong, Y., & Wong, N. D. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07403-2 · Cited by 24
Umpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 22
Chan, Y., Chen, S., Chao, T., Kao, Y., Huang, C.-Y., & Chu, P. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01285-8 · Cited by 21
Jhuo, S., Lin, T., Lin, Y., Tsai, W., Liu, I.-H., Wu, B., Lee, K., & Lai, W. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020271 · Cited by 22
Jhuo, S., Lin, Y., Liu, I.-H., Lin, T., Wu, B., Lee, K., & Lai, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076842 · Cited by 21
Sampani, E., Sarafidis, P. A., & Papagianni, A. A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1764532 · Cited by 24
Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
Cappetta, D., Angelis, A. D., Bellocchio, G., Telesca, M., Cianflone, E., Torella, D., Rossi, F., Urbanek, K., & Berrino, L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.810791 · Cited by 21
Yi, T. W., O’Hara, D. V., Smyth, B. J., Jardine, M., Levin, A., & Morton, R. L. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581231217857 · Cited by 20
The role of myocardial fibrosis in the diabetic cardiomyopathy
Sun, J., Zhou, R., Liu, M., & Zhang, D. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01783-9 · Cited by 22
Young, S. L., Ryan, L., MULLINS, T. P., Flint, M., Steane, S. E., Walton, S. L., Bielefeldt‐Ohmann, H., Carter, D. A., Reichelt, M. E., & Gallo, L. A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.738594 · Cited by 21
Self-citationHan, Y., Cheng, B., Guo, Y., Wang, Q., Yang, N., & Lin, P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.779636 · Cited by 23
SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
Kansara, A., Mubeen, F., & Shakil, J. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1120 · Cited by 22
Algal metabolites: Paving the way towards new generation antidiabetic therapeutics
Kaushik, A., Sangtani, R., Parmar, H. S., & Bala, K. (2022) · Algal Research · doi:10.1016/j.algal.2022.102904 · Cited by 21
Zhang, L., Zhang, F., Bai, Y., Huang, L., Zhong, Y., & Zhang, X. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003836 · Cited by 20
A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes
Neeland, I. J., Salahuddin, U., & McGuire, D. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1135900 · Cited by 20
Kato, E. T., & Kimura, T. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0013 · Cited by 21
SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
Tamez-Pérez, H. E., Delgadillo-Esteban, E., Soni-Duque, D., Hernández-Coria, M. I., & Tamez-Peña, A. L. (2017) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-017-0308-4 · Cited by 19
Jhuo, S., Liu, I.-H., Tasi, W.-C., Chou, T.-W., Lin, Y., Wu, B., Lee, K., & Lai, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116105 · Cited by 19
New Approaches to Cardiovascular Disease and Its Management in Kidney Transplant Recipients
Aziz, F., Jorgenson, M., Garg, N., Parajuli, S., Mohamed, M., Raza, F., Mandelbrot, D. A., Djamali, A., & Dhingra, R. (2021) · Transplantation · doi:10.1097/tp.0000000000003990 · Cited by 21
A review of sotagliflozin for use in type 1 diabetes
Nuffer, W. A., Williams, B., & Trujillo, J. M. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819890527 · Cited by 20
SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease
Júnior, P. A. B. M., Lass, A. D., Pilger, B. I., Fornazari, R., de Moraes, T. P., & Pinho, R. A. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2023-0187en · Cited by 18
Kostrzewska, P., Kuca, P., Witek, P., Małyszko, J., Madetko‐Alster, N., & Alster, P. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00832-9 · Cited by 20
Zhao, B., Shen, J., Zhao, J., & Pan, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13481 · Cited by 17
Energy metabolism homeostasis in cardiovascular diseases.
Wang, L.-Y., & Chen, C. (2021) · PubMed Central · doi:10.11909/j.issn.1671-5411.2021.12.006 · Cited by 18
Teo, Y. H., Chia, A. Z. Q., Teo, Y. N., Chong, E. Y., Syn, N. L. X., Cheong, J. Y. A., Ong, H. T., Wee, C. F., Ting, A. Z. H., Tan, J. T. A., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003280 · Cited by 18
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Chan, J. C. H., & Chan, M. C. Y. (2023) · Medicina · doi:10.3390/medicina59020388 · Cited by 25
Wang, Z., Hu, X., Liu, X., & Wang, Y. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s112236 · Cited by 18
Zhang, J., Li, L., Liu, C., Li, P., & Yu, C. (2019) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000146 · Cited by 18
Alkabbani, W., & Gamble, J. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s281602 · Cited by 18
Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan
Kodera, S., Morita, H., Nishi, H., Takeda, N., Ando, J., & Komuro, I. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0086 · Cited by 18
Moumouni, A. N. A., Robin, P., Hillaire‐Buys, D., & Faillie, J. (2017) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12334 · Cited by 18
Uric acid in diabetic microvascular complications: Mechanisms and therapy
Li, X., Huang, B., Liu, Y., Wang, M., & Cui, J. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108929 · Cited by 18
Burin, S. L., Lourenço, R. L., Doneda, M., Müller, E. I., Paula, F. R., & Adams, A. I. H. (2020) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmaa129 · Cited by 17
A profile of SGLT-2 inhibitors in hyponatremia: The evidence to date
Tang, H., Xu, C., Zhang, P., Luo, T., Huang, Y., & Yang, X. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106415 · Cited by 17
d’Aiello, A., Bonanni, A., Vinci, R., Pedicino, D., Severino, A., Vita, A. D., Filomia, S., Brecciaroli, M., & Liuzzo, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108643 · Cited by 18
Zhang, T., Wang, X., Wang, Z., Zhai, J., He, L., Wang, Y., Zuo, Q., Ma, S., Zhang, G., & Guo, Y. (2023) · Pharmacology · doi:10.1159/000533277 · Cited by 17
Li, L., Liu, H., Chai, Q., Wei, J., Qin, Y., Yang, J., Liu, H., Qi, J., Guo, C., & Lu, Z. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05486-8 · Cited by 17
DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.
Paneni, F. (2015) · PubMed Central · doi:10.3978/j.issn.2223-3652.2015.09.06 · Cited by 17
New Agents for the Treatment of Type 2 Diabetes
Libianto, R., & Ekinci, E. I. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.007 · Cited by 18
Chen, H., Yang, Y., Yu, T.-H., & Li, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175354 · Cited by 16
Seki, H., Kuratani, N., Shiga, T., Iwasaki, Y., Karita, K., Yasuda, K., Yamamoto, N., Nakanishi, Y., Shigematsu, K., Kobayashi, K., et al. (2024) · Journal of Anesthesia · doi:10.1007/s00540-024-03335-3 · Cited by 16
Peng, Y., Guo, M., Luo, M., Lv, D., Liao, K., Luo, S., & Zhang, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29160 · Cited by 16
Hinton, W., Feher, M. D., Munro, N. M., Joy, M., & de Lusignan, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01316-4 · Cited by 15
Pathan, M. F., Akter, N., Selim, S., Saifuddin, M., Qureshi, N. K., Kamrul-Hasan, A. B. M., Hannan, M. A., Ahmed, M. A. U., Mustari, M., & Chakraborty, A. K. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s380544 · Cited by 16
Kuroda, S., Kobashi, Y., Oi, T., Kawabe, K., Shiozawa, F., Okumura-Kitajima, L., Sugisaki-Kitano, M., Io, F., Yamamoto, K., & Kakinuma, H. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.12.015 · Cited by 16
New and emerging cardiovascular and antihypertensive drugs
Chrysant, S. G., & Chrysant, G. S. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1810232 · Cited by 15
Herat, L. Y., Matthews, J. R., Hibbs, M. E., Rakoczy, E. P., Schlaich, M. P., & Matthews, V. B. (2022) · iScience · doi:10.1016/j.isci.2023.107260 · Cited by 18
Metadata
- Authors
- Gallo, L. A., Wright, E. M., & Vallon, V.
- Affiliations
- Translational Research Institute (AU)
- University of California, Los Angeles (US)
- University of California San Diego (US)
- Venue
- Diabetes and Vascular Disease Research
- Publisher
- SAGE Publications
- Published
- 2015-01-23
- Volume
- 12
- Issue
- 2
- Pages
- 78-89
- ISSN
- 1479-1641 (ISSN-L)
- 1752-8984
- PMC
- PMC5886707
- OpenAlex
- W2142065502
- Cited by
- 395
- References
- 92
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 45 · 2023: 33 · 2022: 45 · 2021: 60 · 2020: 47 · 2019: 30 · 2018: 36 · 2017: 20 · 2016: 19 · 2015: 16
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes and Vascular Disease Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL094728)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK19567, R01 DK-56248, R01DK019567, P30DK079337, R01DK056248)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, type 1 diabetes, type 2 diabetes, renal glucose reabsorption, proximal tubule, SGLT1, urinary glucose excretion, hyperglycemia, cardiovascular risk, drug safety, insulin-independent glucose lowering
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Kidney Tubules, Proximal, Treatment Outcome, Sodium-Glucose Transporter 1, Sodium-Glucose Transporter 2, Molecular Targeted Therapy, Renal Reabsorption, Renal Elimination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
